In summary, throughout the last 10 years the most spectacular edge has been reached in HER2/neu-overexpressing MBC. Introduction of bevacizumab like a VEGF-directed specific treatment remains a difficulty on debate. Some of the novel therapeutics for the breast cancer armamentarium resulted in prolongation of survival for people with MBC. At the mo